Nonsteroidal mineralocorticoid receptor antagonist finerenone ameliorates cardiac hypertrophy with increasing glucocorticoid signaling sensitivity

Finerenone alleviates early-stage cardiac hypertrophy in a murine HFpEF model driven by metabolic and hemodynamic stress. Its cardioprotective effects appear to be independent of systemic blood pressure reduction and may involve modulation of GR signaling pathways in cardiomyocytes.